Get started

Financials · IMDX

Insight Molecular Diagnostics Inc. (IMDX) financials

For the twelve months ended Jun 30, 2026, Insight Molecular Diagnostics Inc. reported $1.67M of revenue and -$49.36M of net income.

Revenue, TTM
$1.67M
Revenue growth, YoY
-60.8%
Net income, TTM
-$49.36M
Net margin
-2955.6%
Free cash flow, TTM
-$31.00M
Cash
$17.76M
P/S
48.99
Market cap
$81.8M
Annual revenue$4.05M
FY2020FY2025
Annual net income-$50.22M
FY2016FY2025
Annual free cash flow-$25.37M
FY2016FY2025

IMDX revenue and earnings growth

IMDX revenueQ2 2026$239.0K

Quarter YoY
-53.9%
QoQ
+646.9%
FY YoY
+115.6%
5Y CAGR
+27.2%

IMDX revenue was $239.0K in fiscal Q2 2026 (ended Jun 30, 2026), down 53.9% from a year earlier and up 646.9% from the prior quarter. For the full fiscal 2025 it was $4.05M, up 115.6% from fiscal 2024. Compound annual growth was +27.2% over 5 years. It rose in 4 of the last 5 fiscal years. Fiscal 2025 is the highest of the 7 fiscal years on file.

IMDX net incomeQ2 2026-$11.26M

IMDX net income was -$11.26M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$9.74M a year earlier. For the full fiscal 2025 it was -$50.22M, compared with -$60.66M in fiscal 2024.

IMDX EPSQ2 2026-$0.31

IMDX diluted EPS was -$0.31 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.30 a year earlier. For the full fiscal 2025 it was -$1.65.

IMDX free cash flowQ2 2026-$10.05M

IMDX free cash flow was -$10.05M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$6.52M a year earlier. For the full fiscal 2025 it was -$25.37M, compared with -$21.20M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$4.05M$1.88M$1.50M$958.0K$2.20M$1.22M----
Cost of revenue$1.75M$1.05M$1.00M$880.0K$697.0K$1.85M----
Gross profit$2.30M$740.0K$413.0K-$18.0K$1.42M-$639.0K----
Research and development$15.90M$9.84M$9.29M$7.30M$5.04M$9.80M$6.79M$6.51M$7.17M$5.68M
Selling, general and admin$10.63M$10.20M$11.18M$21.88M$22.29M$16.79M$13.28M$7.01M$9.23M$4.26M
Operating income-$51.12M-$61.04M-$25.14M-$18.00M-$53.73M-$29.71M-$22.24M-$15.20M-$18.85M-$11.14M
Interest expense---------$0
Pre-tax income--$60.66M-$24.86M-$18.61M-$52.87M-$31.19M-$22.43M---
Income tax$0$0$0--$9.26M-$1.25M----
Net income-$50.22M-$60.66M-$27.78M-$72.90M-$64.10M-$29.93M-$22.43M-$15.75M-$19.38M-$11.17M
EPS, basic-$1.65-$4.66-$3.75-$13.25-$0.72-$0.46-$0.44-$0.42-$0.64-$0.42
EPS, diluted-$1.65-$4.66-$3.75-$13.25-$0.72-$0.46-$0.44-$0.42-$0.64-$0.42
Diluted shares30.5M13.1M7.7M5.5M88,92065,47851.3M37.9M30.2M26.5M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$11.58M$8.64M$9.43M$19.99M$32.95M$7.14M$22.07M$8.03M$7.60M$10.17M
Receivables$1.13M$1.61M$484.0K$2.01M$1.44M$203.0K----
Inventory$446.0K$410.0K--------
Current assets$15.31M$11.76M$10.70M$25.54M$39.14M$9.23M$22.96M$8.64M$8.53M$12.70M
Goodwill----$18.68M$9.19M----
Total assets$25.76M$35.08M$74.89M$100.09M$159.56M$55.42M$39.86M$9.52M$10.22M$14.45M
Current liabilities$12.07M$7.28M$7.19M$12.11M$14.12M$9.00M$4.44M$5.56M$4.45M$4.28M
Total debt--------$1.87M-
Total liabilities$57.22M$47.35M$49.30M$60.50M$94.35M$21.94M$9.02M$6.09M$5.81M$4.58M
Shareholders' equity-$31.46M-$12.27M$20.47M$34.29M$65.22M$33.48M$30.84M$3.42M$4.40M$9.86M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$22.18M-$20.69M-$23.32M-$45.57M-$35.94M-$25.98M-$19.71M-$11.65M-$13.38M-$7.52M
Capital expenditures$3.19M$516.0K$281.0K$4.34M$2.25M$1.23M$918.0K$31.0K$91.0K$106.0K
Free cash flow-$25.37M-$21.20M-$23.61M-$49.91M-$38.19M-$27.21M-$20.63M-$11.68M-$13.48M-$7.63M
Investing cash flow-$3.19M-$512.0K-$932.0K-$4.34M-$13.96M-$11.75M-$12.41M-$31.0K$843.0K-$181.0K
Financing cash flow$28.07M$20.43M$12.19M$35.81M$78.36M$22.80M$47.87M$12.11M$9.97M$9.88M
Stock-based compensation$2.22M$1.75M$2.76M$10.04M$6.84M$5.07M$3.00M$1.48M$1.63M-
Depreciation and amortization$2.20M$1.56M$1.68M$1.53M$800.0K$313.0K----

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY115.6%25.1%56.9%-56.4%80.8%-----
Gross margin56.7%39.3%27.5%-1.9%64.6%-52.5%----
Operating margin-1260.8%-3245.1%-1672.4%-1878.6%-2444.3%-2443.3%----
Net margin-1238.5%-3225.0%-1848.4%-7609.8%-2916.2%-2461.5%----
Free cash flow margin-625.6%-1127.3%-1570.6%-5209.6%-1737.4%-2237.4%----
Return on equity---135.7%-212.6%-98.3%-89.4%-72.7%-460.2%-440.0%-113.2%
Return on assets-195.0%-172.9%-37.1%-72.8%-40.2%-54.0%-56.3%-165.5%-189.7%-77.3%
Current ratio1.271.621.492.112.771.035.171.551.912.97
Debt to equity--------0.42-

Source: XBRL data Insight Molecular Diagnostics Inc. files with the SEC, latest filing dated Aug 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

IMDX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
IMDX$1.67M-60.8%-$49.36M-2955.6%$81.8M
IDXX$4.66B+11.9%$1.18B25.4%$55.67B
ORKA---$152.57M-$6.92B
LNTH$1.56B+2.4%$269.90M17.3%$6.61B
NEOG$883.99M-0.3%-$56.10M-6.3%$2.64B
CLDX$158.0K-93.9%-$309.06M-195608.9%$2.45B
NTLA$52.89M-8.1%-$426.14M-805.7%$1.70B
QDEL$2.59B-4.5%-$369.20M-14.2%$829.5M
ACHV---$114.04M-$697.7M

IMDX FAQ

8 questions
  • What is IMDX revenue?
    Insight Molecular Diagnostics Inc. (IMDX) reported $1.67M of revenue for the twelve months ended Jun 30, 2026. That is down 60.8% from the year before. Revenue for fiscal 2025 was $4.05M.
  • Is IMDX profitable?
    No. Insight Molecular Diagnostics Inc. reported a net loss of $49.36M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does IMDX have?
    Insight Molecular Diagnostics Inc. reported $17.76M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is IMDX revenue growing?
    Insight Molecular Diagnostics Inc.'s revenue changed +115.6% in fiscal 2025, to $4.05M. Its compound annual growth rate was +27.2% over 5 years.
  • What is IMDX gross margin?
    Insight Molecular Diagnostics Inc.'s gross profit was $807.0K on $1.67M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 48.3%.
  • What is IMDX free cash flow?
    Insight Molecular Diagnostics Inc. generated -$31.00M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$27.08M less capital expenditures.
  • When did IMDX last report financial results?
    The latest statements here come from Insight Molecular Diagnostics Inc.'s 10-Q filed on Aug 10, 2026, covering the period ended Jun 30, 2026.
  • Where does this IMDX financial data come from?
    Quantisnow builds these statements from the structured XBRL data Insight Molecular Diagnostics Inc. files with the SEC. It is provided for information only and is not investment advice.